NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events

NCT07734753

Active Not RecruitingN/A

Sponsor: Sanofi

Conditions: Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events

Interventions: Alirocumab, Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)

Countries: Netherlands

To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adults aged ≥18 years with documented ASCVD between January 1, 2016, and September 30, 2024.
* No history of myocardial infarction, ischemic stroke, or hospitalization for unstable angina on or before the index date.
* Minimum of 12 months of continuous healthcare data availability prior to the index date
* No exposure to any PCSK9 inhibitor in the 2 years preceding the index date.

Exclusion Criteria:

\- Participants with a history of prior ischemic events.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Locations (1)

Amsterdam, Netherlands